These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18465026)

  • 41. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
    McNaught KS; Perl DP; Brownell AL; Olanow CW
    Ann Neurol; 2004 Jul; 56(1):149-62. PubMed ID: 15236415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of Src protein in the process formation of PC12 cells induced by the proteasome inhibitor MG-132.
    Tarjányi O; Berta G; Harci A; Bacsa EB; Stark B; Pap M; Szeberényi J; Sétáló G
    Neurochem Int; 2013 Nov; 63(5):413-22. PubMed ID: 23911694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of proteasome inhibition by MG-132 on HSP27 oligomerization, phosphorylation, and aggresome formation in the OLN-93 oligodendroglia cell line.
    Bolhuis S; Richter-Landsberg C
    J Neurochem; 2010 Aug; 114(4):960-71. PubMed ID: 20089131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery.
    Meimaridou E; Gooljar SB; Chapple JP
    J Mol Endocrinol; 2009 Jan; 42(1):1-9. PubMed ID: 18852216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132.
    Zhou Z; Kerk S; Meng Lim T
    Free Radic Res; 2008 May; 42(5):456-66. PubMed ID: 18484277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat.
    Holecek M; Muthny T; Kovarik M; Sispera L
    Biochem Biophys Res Commun; 2006 Jun; 345(1):38-42. PubMed ID: 16674919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Similarities between methamphetamine toxicity and proteasome inhibition.
    Fornai F; Lenzi P; Gesi M; Ferrucci M; Lazzeri G; Capobianco L; de Blasi A; Battaglia G; Nicoletti F; Ruggieri S; Paparelli A
    Ann N Y Acad Sci; 2004 Oct; 1025():162-70. PubMed ID: 15542714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones.
    Fortun J; Verrier JD; Go JC; Madorsky I; Dunn WA; Notterpek L
    Neurobiol Dis; 2007 Feb; 25(2):252-65. PubMed ID: 17174099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limbic structures are prone to age-related impairments in proteasome activity and neuronal ubiquitinated inclusions in SAMP10 mouse: a model of cerebral degeneration.
    Shimada A; Keino H; Kawamura N; Chiba Y; Hosokawa M
    Neuropathol Appl Neurobiol; 2008 Feb; 34(1):33-51. PubMed ID: 17973906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Partial rescue of geldanamycin-induced TrkA depletion by a proteasome inhibitor in PC12 cells.
    Berta G; Harci A; Tarjányi O; Vecsernyés M; Balogh A; Pap M; Szeberényi J; Sétáló G
    Brain Res; 2013 Jul; 1520():70-9. PubMed ID: 23701727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome.
    Westhoff B; Chapple JP; van der Spuy J; Höhfeld J; Cheetham ME
    Curr Biol; 2005 Jun; 15(11):1058-64. PubMed ID: 15936278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
    Stenoien DL; Mielke M; Mancini MA
    Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells.
    Yoshimoto Y; Nakaso K; Nakashima K
    FEBS Lett; 2005 Feb; 579(5):1197-202. PubMed ID: 15710413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chaperone-driven proteasome assembly.
    Rosenzweig R; Glickman MH
    Biochem Soc Trans; 2008 Oct; 36(Pt 5):807-12. PubMed ID: 18793141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals.
    Le Tallec B; Barrault MB; Courbeyrette R; Guérois R; Marsolier-Kergoat MC; Peyroche A
    Mol Cell; 2007 Aug; 27(4):660-74. PubMed ID: 17707236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lamotrigine Attenuates Proteasome Inhibition-Induced Apoptosis by Suppressing the Activation of the Mitochondrial Pathway and the Caspase-8- and Bid-Dependent Pathways.
    Nam YJ; Kim A; Lee MS; Shin YK; Sohn DS; Lee CS
    Neurochem Res; 2016 Oct; 41(10):2503-2516. PubMed ID: 27230883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteotoxic stresses stimulate dissociation of UBL4A from the tail-anchored protein recognition complex.
    Hagiwara T; Minami R; Ushio C; Yokota N; Kawahara H
    Biochem J; 2023 Oct; 480(19):1583-1598. PubMed ID: 37747814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular Spasm: A Newly Unraveled Cause for Cardiovascular Adversity of Proteasome Inhibition.
    Wang X
    EBioMedicine; 2017 Jul; 21():51-52. PubMed ID: 28629913
    [No Abstract]   [Full Text] [Related]  

  • 60. Keratin inclusions alter cytosolic protein localization in hepatocytes.
    Hanada S; Harada M; Kawaguchi T; Kumemura H; Taniguchi E; Koga H; Yanagimoto C; Maeyama M; Ueno T; Sata M
    Hepatol Res; 2007 Oct; 37(10):828-35. PubMed ID: 17573944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.